Last reviewed · How we verify

NCT05457322: RELAX

The RELAX Trial: Nonpharmaceutical Intervention for Nocturnal Muscle Cramps

Completed NA Last updated 11 September 2023
What this trial tests

NA trial testing Behavioral intervention one in Cramps in 99 participants. Completed in 14 August 2023.

Timeline
30 August 2022
Primary endpoint
14 August 2023
14 August 2023

Quick facts

Lead sponsorUniversity of Michigan
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment99
Start date30 August 2022
Primary completion14 August 2023
Estimated completion14 August 2023
Sites6 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Michigan

Who can join

18 and older, any sex, with Cramps or Muscle Cramp. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to learn about reducing the symptoms and severity of nighttime lower body muscle cramps in patients with and without cirrhosis. Eligible participants will have an initial 7-day practice phase, followed by 28 days of one of two behavioral interventions.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. The RELAX randomized controlled trial: Stretching versus meditation for nocturnal muscle cramps.
    Tapper EB, Trivedi H, Simonetto DA, Patwardhan V, et al · · 2024 · cited 5× · PMID 38860445 · DOI 10.1111/liv.16007
  2. Muscle cramps in cirrhosis.
    Gonzalez JJ, Tapper EB. · · 2024 · cited 4× · PMID 38283307 · DOI 10.1097/cld.0000000000000116

Verify or expand the search:

Other University of Michigan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05457322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing